The Company is committed to leveraging its products and services to establish a potential new standard of care across multiple malignant tumor applications.
The Company is a healthcare solution provider dedicated to the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors.
FTTPS is technologically advanced and has a wide range of clinical indications. FTTPS is widely used in diseases caused by many types of malignant tumors, including but not limited to prostate cancer, lung cancer, pancreatic cancer, liver cancer, esophageal cancer, and breast cancer.
The Company offers personalized and inclusive services that catered to the specific requirements of its clients.
公司致力于利用我們的產品和服務，在多種惡性腫瘤應用中建立潛在的新護理標準。
我們是一家醫療解決方案提供商，致力于開發和商業化專門用于放射性粒籽植入的近距離治療計劃軟件，粒籽植入治療是一種通過在患者體內放置放射源來殺死癌細胞和縮小腫瘤的治療癌癥患者的放射療法。
FTTPS技術先進，具有廣泛的臨床適應癥。FTTPS廣泛應用于多種惡性腫瘤引起的疾病，包括但不限于前列腺癌、肺癌、胰腺癌、肝癌、食管癌、乳腺癌等。
公司提供根據客戶的具體要求提供個性化和包容性的服務。
The Company focuses on key growth strategies to realize its mission:
· Enhance ability to attract, incentivize and maintain good relationships with talented professionals. The Company believes its success greatly depends on the ability to attract, incentivize and maintain long-term relationships with talented professionals. In addition, the Company aims to keep long-term relationships with third-party development teams or experts.
· Continue to invest in research and development. The Company attributes part of its success to our continued investment in and focus on R&D.
The Company emphasizes quality control in all aspects of its operations to ensure its products meet stringent internal standards, international and industry standards, as well as detailed requirements of various laws and regulations relating to medical devices, including but not limited to the registration and filings for medical devices, the production and operation license, the production and quality management.
The TPS market is characterized by rapid product development, technological advances, intense competition and a strong emphasis on proprietary products. Across all product lines and product tiers, The Company faces direct competition both domestically in China and internationally. Factors such as price, value, customer support, brand recognition, reputation, and product functionality, reliability, and compatibility are key considerations in the competition.
As of 2021, Beijing Feitian holds a market share of 60.2% in terms of the total number of installed brachytherapy TPS in the market.
The Company’s mission is to provide innovative healthcare solutions and world-class service to become a reliable partner with hospitals, physicians and patients.
公司專注于關鍵發展戰略以實現其使命：
· 提高吸引、激勵人才并與之保持良好關系的能力。公司相信其成功在很大程度上取決于吸引、激勵和保持與有才能的專業人士的長期關系的能力。此外，公司旨在與第三方開發團隊或專家保持長期合作關系。
· 持續投資研究開發。公司的成功部分歸功于其對研發的持續投資和專注。
公司在經營的各個環節都注重質量控制，確保產品符合嚴格的內部標準、國際標準和行業標準，以及與醫療器械有關的各種法律法規的詳細要求，包括但不限于醫療器械的注冊和備案、生產經營許可證、生產和質量管理。
治療計劃軟件市場的特點是產品開發迅速，技術進步，競爭激烈，并著重強調專有產品。在所有產品線和產品層次上，公司在中國國內和國際上都面臨著直接競爭。價格、價值、客戶支持、品牌識別、聲譽、產品功能、可靠性和兼容性等因素是競爭中的關鍵考慮因素。
截至2021年，北京飛天在近距離治療TPS的安裝總量中占有60.2%的市場份額。
我們的使命是提供創新醫療解決方案和世界一流的服務，成為醫院、醫生和患者可靠的合作伙伴。
|
